Janssen gets FDA’s green light for Xarelto for prevention of blood clots

The U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, Janssen said Monday in a press release.

Read more

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com

The global anticoagulants reversal drugs market expected to expand at aCAGR of 15.3% from 2018 to 2026, owing to the approval of blockbusterdrugs in recent years and strong pipeline driving the market.

Read more